Source: Antisense Therapeutics LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Antisense Therapeutics (ANP) submits its first clinical trial application for the Phase 2b/3 clinical trial of its drug aiming to treat muscular dystrophy
  • The application has been submitted to the Federal Institute for Drugs and Medical Devices in Germany for evaluation and approval
  • The company says the submission is a milestone moment as it works to establish a regulatory pathway with the European Medicines Agency
  • It is working to optimise its capital management process for the drug’s development to ensure effective use of its existing cash reserves
  • Shares are trading 1.20 per cent higher today at 8.4 cents each at 11:20 am AEST.

Antisense Therapeutics (ANP) has submitted its first clinical trial application for the Phase 2b/3 clinical trial of ATL1102.

ATL1102 aims to treat patients with muscular dystrophy who are unable to walk.

The application was submitted to the Federal Institute for Drugs and Medical Devices in Germany for evaluation and approval.

The company said the application submission was a milestone moment as it works to establish a regulatory pathway with the European Medicines Agency.

Antisense has been working to optimise its capital management process for the drug’s development to ensure effective use of its existing cash reserves.

Shares were trading 1.20 per cent higher today at 8.4 cents each at 11:20 am AEST.

ANP by the numbers
More From The Market Herald
Melbana Energy (ASX:MAY) - Executive Chairman, Andrew Purcell (left)

" Melbana Energy (ASX:MAY) reaches 2150m depth at Zapato-1, Cuba

Melbana Energy (ASX:MAY) has reached a depth of 2150 metres at the side-track hole in its…

" Metal Hawk (ASX:MHK) identifies DHEM conductor at Torana, WA

Metal Hawk (ASX:MHK) identifies an off-hole conductor at the Torana prospect within its Berehaven project in…
The Market Herald Video

" Horizon Minerals (ASX:HRZ) gets “excellent” drill results at Monument, WA

Horizon Minerals (ASX:HRZ) reports "excellent" results from the Monument gold prospect in WA.
The Market Herald Video

" New Age Exploration (ASX:NAE) granted Marlborough project, NZ

New Age Exploration (ASX:NAE) is granted a prospecting permit which covers the Marlborough gold project in…